Anavex Life Sciences Corp (AVXL)

[abew4me]

Whenever someone asks for specific (new) data to compare against the old CTAD data that was removed, I always referred to the post by one of the MB members back on February 17th; because it explains why Anavex took down all of the old slide decks for the P2b/3 trial. (See the post below)

hnbadger
Friday, February 17, 2023

This is from AVXL IR:
The company is working on another
video and an upcoming press release
that will address many of the
questions that you asked. Moreover,
some of the answers will elaborate
on specifics, all of which we believe
will provide a thorough
understanding of our initiatives. At
this time some of your questions can
not be answered today, because new,
updated data will be available to us
in the near future, all of which we
would need to disseminate such
information in accordance with
Regulation FD - via press releases
and/or 8k filing, not through an
individual email or one-on-one
conversation.
Thanks 100fold from ST


Now, fast-forward to this month and we finally see that, yes, Anavex was indeed receiving new data that nullified the previous CTAD data. (See below)

"With newly available preliminary efficacy results of surrogate biomarkers, we consider initiating discussions with regulatory agencies for Accelerated Approval Pathway for ANAVEX2-73. In parallel, we plan to proceed with the initiation of our confirmatory Alzheimer’s disease study."

https://www.insidermonkey.com/blog/anavex-life-sciences-corp-nasdaqavxl-q2-2023-earnings-call-transcript-1149124/


So, until we receive all of the updated data from the P2b/3 trial it would be senseless to try and answer your question. (And btw, I think Doc already knows that too.)

Hope this satisfies your inquiry.

abe